Pharmaceutical

Fast track your best drug discovery candidates with confidence

Use our transformative approach for high quality in vivo data early, to de-risk your pipeline

Our expert CRO services provide our Pharmaceutical partners with high-quality, robust in vivo data to help prioritise and progress their best clinical candidates within weeks. We combine the advantages of C.elegans as a model organism, with our world-leading expertise for validated, regulation-free testing with human translatability. 

Unique technology and expertise

Our fast, economical approach helps augment in vitro studies, and provides predictive in vivo data to de-risk your project — reducing the need for mammalian testing. Our interdisciplinary team bring 80+ years joint C. elegans experience, and we work together to bring you the optimal assays for pharmaceutical applications.

Our unique bio-photonics platform technology — WormGazerTM, differentiates us significantly from competitors. WormGazerTM generates scalable, multi-end point data for a comprehensive efficacy and safety profile. 

We work efficiently to meet diverse data requirements for efficacy, early toxicology, phenotypic and functional endpoints, drug combinations, mechanism of action, target validation and identification. Our transgenics strains can be tailored to your project needs, including custom disease and humanised models.

Scalable, in vivo data to prioritise clinical candidates 

✓  A validated 3R compliant in vivo model for acute and chronic drug testing

✓  Scalable data in weeks, with unique automated WormGazerTM technology 

✓  De-risk and reduce rodent testing and regulation

✓ Radically reduce timelines and costs, moving from in vitro to in vivo studies

✓ Transgenic strains tailored to the exact needs of your project 

✓ Bespoke CRO assay development and proof of concept studies 

✓ Expert interdisciplinary team with 80+ years joint experience as partners 

✓ Well-structured, robust data for all in-house formats, publication, patents and investors

GeroState Alpha is a pharmaceutical company, based at the Buck Institute for Research on Ageing in Novato, California, US. Their key therapeutic focus is on treating ageing and age-related disease.

They needed to test their lead compounds to establish which was most effective at promoting health and slowing ageing.

Magnitude Biosciences worked with Gerostate Alpha to help the pharmaceutical company prioritise their small molecule candidate pipeline for their effects to delay ageing.

“We are excited to be working with Magnitude Biosciences. Their unique approach to generating in vivo data for studying disease models will help us get fast and reliable answers to our research questions.”

Kjartan Herrik, Principal Scientist at Lundbeck Pharma, Neurodegenerative Disease

Get in touch today to find out how we can 
support you to accelerate your research

Privacy Policy
This field is for validation purposes and should be left unchanged.

SERVICES

Contract lab services for 
your research area

Our customised C. elegans studies help industry leaders generate high-quality, 
reproducible data to answer their research questions in these areas.

Microbiome

A powerful whole
organism model for
microbiome research

Neurodegeneration

A proven whole organism model for neurodegenerative disease
research

Toxicity

A powerful whole organism model for detecting toxicity for the environment and human health

Ageing

A powerful whole
organism model for accelerating ageing research

Transgenics

We can generate C. elegans strains tailored to the exact needs of your project.

Slide
Ageing

A powerful whole
organism model for accelerating ageing research

Slide
Microbiome

A powerful whole organism model for
microbiome research

Slide
Neurodegeneration

A proven whole organism model for neurodegenerative disease
research

Slide
Toxicity

A powerful whole organism model for detecting toxicity for the environment and human health

Slide
Transgenics

We can generate C. elegans strains tailored to the exact needs of your project.

previous arrow
previous arrow
next arrow
next arrow

Get regular updates in your inbox

Sign up to our newsletter today, to get access to the latest company and industry news